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Several known mammalian ribonucleotide reductase inhibitors featuring a polyhydroxyphenyl and/or hy-
droxamate moiety as the active group were screened for potency in inhibiting growth of the malaria parasite
Plasmodium falciparum. Compounds containing a 2,3- or 3,4-dihydroxyphenyl group as well as benzohydrox-
amate appear to be the most effective inhibitors of the malaria parasite.
There is an urgent need to develop antimalarials targeted
against new metabolic targets as the drugs available to fight the
disease are rapidly losing their efficacy. Ribonucleotide reduc-
tase (RNR) catalyzes the reduction of ribonucleotides to de-
oxyribonucleotides, the first and rate-limiting step for de novo
synthesis of 29-deoxyribonucleoside 59-triphosphates (16). RNR
activity has been shown to be closely correlated to the rate of
tumor growth (5, 19); consequently, inhibitors directed against
RNR have been used for many years in cancer chemotherapy
(7, 11, 12). The central role of the ubiquitous enzyme RNR in
DNA metabolism also makes this enzyme an excellent target
for chemotherapy of malaria. We have previously reported that
an oligodeoxynucleotide phosphorothioate complementary to
RNR small subunit sequences showed antimalarial activity (2).
We have now initiated a systematic investigation to test known
RNR inhibitors for possible antimalarial activity. Several anti-
tumor and antiviral compounds exist which are specific inhib-
itors of RNR (15). The hydroxamate groups of RNR inhibitors
such as hydroxyurea are electron reductants and destroy the
tyrosyl radical (6). This paper reports evaluation of hydroxamic
acid and polyhydroxyphenyl derivatives as potential antimalari-
als.
We evaluated three known RNR inhibitors, hydroxyurea,
acetohydroxamate, and benzohydroxamate, for potential anti-
malarial activities in synchronous Plasmodium falciparum Dd2-
infected erythrocyte culture according to the method of Des-
jardins et al. (3). Ring-stage cultures were incubated with [3H]
hypoxanthine (1 mCi/ml; 1 mCi 5 37 kBq) and various concen-
trations of inhibitors for 24 h at 37°C. The radiolabeled geno-
mic DNA was isolated by sodium dodecyl sulfate-proteinase K
treatment (14) and counted with a liquid scintillation spec-
trometer. The data were analyzed by logistic regression (11)
since experimental variance is not constant for all drug con-
centrations, which makes the standard least squares technique
inappropriate. This type of analysis was conducted for each
drug evaluated to produce curves from which the drug concen-
tration inhibiting 50% of the parasite growth (IC50) was cal-
culated.
As can be seen in Table 1, both hydroxyurea and acetohy-
droxamate were weak inhibitors of malaria parasite growth.
However, the IC50 for benzohydroxamic acid was about 50-fold
lower than that for either hydroxyurea or acetohydroxamate.
Some trends emerge from these data which encourage us in
thinking that RNR could be a promising antimalarial target.
Hydroxyurea and benzohydroxamate inhibit mammalian RNR
to similar extents with IC50s of 500 and 400 mM, respectively
(7). We found benzohydroxamate to be a much more effective
inhibitor of malaria parasite growth than hydroxyurea, requir-
ing a 20-fold lower concentration to effect the same level of
inhibition as that of the human enzyme. The fact that benzo-
hydroxamic acid proved to be a much more potent inhibitor of
P. falciparum than the human system is noteworthy for two
reasons. Not only does this identify benzohydroxamate as a
potential antimalarial, but in addition and perhaps more im-
portantly, it provides evidence of a difference between P. fal-
ciparum and human RNRs. This evidence supports that of Klay-
man et al. (9, 10), who cured Plasmodium berghei malaria in
mice with RNR inhibitors, suggesting a possible difference
between the P. berghei and mouse forms of reductase. Unlike
the P. berghei data, the P. falciparum result presented here
could not be explained by a difference in drug permeability,
since benzohydroxamate was more effective in inhibiting the
P. falciparum reductase enclosed within the parasite than the
human enzyme, which was free in solution.
The results suggesting a difference between P. falciparum
and human RNRs prompted us to test several substituted or
modified forms of benzohydroxamate, such as vicinal polyhy-
droxyphenyl-containing compounds. This family of compounds
has demonstrated antitumor activity, presumably due to inhi-
bition of RNR activity (6–8, 17). We focused on vicinal di- and
trihydroxyphenyls both with and without a hydroxamate moi-
ety. The positions of the hydroxyl groups were varied; in ad-
dition, one drug (VF268) had nonadjacent hydroxyls and on
another (VF282) the hydroxyl hydrogens were replaced with a
methyl group.
Polyhydroxyphenyl and hydroxamic acid compounds are ef-
fective metal chelators. Since a ferric iron center plays a key
role in RNR activity, the metal-chelating capacity of these
compounds could explain their ability to inhibit RNR. Al-
though it has been shown that changing hydroxyl group posi-
tions on the benzene ring has little effect on Fe31-chelating
activity if hydroxamic acid is present (7), such changes have
large and correlative effects on RNR inhibition and free rad-
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ical quenching potency (4). Hence, the mechanism by which
polyhydroxyphenyls inhibit RNR is now believed to be free
radical scavenging. Table 2 provides the structure and a sum-
mary of test results for each drug tested. VF149 and VF147,
the two vicinal dihydroxybenzohydroxamates tested, outper-
formed the other drugs as inhibitors of P. falciparum growth.
Trihydroxyphenyl-containing compounds are more effective
mammalian RNR inhibitors than are compounds which con-
TABLE 1. Antimalarial activities of hydroxamic acidsa
Compound and structure IC50(mM)
95% upper bound
(mM)
95% lower bound
(mM)
No. of
tests
Aminohydroxamate (hydroxyurea) 792 .10,000 97 58
Acetohydroxamate 1,032 3,912 26.4 60
Benzohydroxamate 17.1 78.5 2.2 76
a Hydroxyurea (Sigma), acetohydroxamate (National Cancer Institute), and benzohydroxamate (National Cancer Institute) were tested in an in vitro culture system
for potential antimalarial activities according to the method of Desjardins et al. (3).
TABLE 2. Antimalarial activities of substituted benzohydroxamic acidsa
Compound Structure IC50(mM)
95% upper bound
(mM)
95% lower bound
(mM)
No. of
tests
VF 149 6.4 25.7 ,1 76
VF 147 15.5 35.5 3.0 68
VF 236 23 80 3.5 52
VF 233 38 185 9.2 51
VF 368 301 .2,000 46 51
VF 268 589 .2,000 91 51
VF 282 2,010 .10,000 520 52
a RNR inhibitors synthesized in one of our laboratories (H.L.E.) were tested on P. falciparum cultures.
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tain one fewer hydroxyl group but are otherwise identical (4, 7,
8, 17). Yet we found the reverse to be true when these drugs
were tested as antimalarials. It could be argued that the trihy-
droxyphenyls were at a disadvantage in our test program since
they are not associated with the hydroxamate group. But test-
ing on mammalian systems demonstrated that the hydroxam-
ate functional group is relatively unimportant for antitumor
activity and that the polyhydroxyphenyl group is the primary
source of activity (6). This appears to be further evidence of a
difference between mammalian and malarial forms of RNR,
since hydroxamate-containing agents were the best antimalari-
als. Of the drugs tested, vicinal dihydroxyphenyl-substituted
hydroxamic acids are the most effective antimalarials. The in-
hibitory effect though was reversible at the IC50. At four times
the IC50 the effects of these inhibitors were found to be irre-
versible (data not shown). Didox (VF147, 3,4-dihydroxybenzo-
hydroxamate) has been in clinical trials as an anticancer agent
since 1988 (18). It exhibits low toxicity to the extent that
steady-state concentrations in plasma during treatment (in-
volving 36 h of infusion) are typically near the malaria parasite
IC50 of 15 mM (1). Didox also stimulated hemoglobin F pro-
duction in an anemic baboon and transgenic mice (13), an
added benefit for malaria patients with anemia. Efforts are
under way to characterize the mechanisms of action of these
inhibitors in in vitro assays with recombinant malarial RNR.
We thank Michelle Fluegge and Cherie DelVecchio for technical
assistance.
This investigation was supported by a grant (AI40692) from the
National Institutes of Health.
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